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Background: This retrospective cohort study aims to compare surgical margins, reoperations and local
recurrences after conventional or oncoplastic breast conservation surgery (BCS). Furthermore, we aim to
investigate differences between various oncoplastic techniques.
Material and methods: We reviewed 1800 consecutive patients with primary invasive breast cancer
(N¼ 1707) or ductal carcinoma in situ (N¼ 93) who underwent BCS at Helsinki University Hospital
between 2010 and 2012.
Results: Conventional BCS was performed in 1189 (66.1%) patients, oncoplastic BCS in 611 (33.9%).
Various oncoplastic techniques were used. Patients with oncoplastic BCS had more often multifocal
(p < 0.001), larger (p< 0.001), palpable tumours (p < 0.001) with larger resection specimens (p < 0.001).
The amount of resected tissue varied substantially depending on the oncoplastic technique. Patients
treated with oncoplastic BCS were younger (p< 0.001) and their tumours were more aggressive ac-
cording to histological grade (p< 0.001), T-stage (p < 0.001), Ki-67 (p< 0.001) and lymph node status
(p < 0.001).
There was no difference, however, in surgical margins (p¼ 0.578) or reoperation rates (p¼ 0.430) be-
tween the groups. A total of 152 (8.4%) patients were reoperated because of insufﬁcient margins, 96
(8.1%) in the conventional, 56 (9.2%) in the oncoplastic BCS group.
The median follow-up time was 75 (2e94) months. There was no difference in local recurrence-free
survival between the conventional and oncoplastic BCS groups (log-rank test, p¼ 0.172).
Conclusions: Oncoplastic BCS was used for larger, multifocal and more aggressive tumours. Nevertheless,
no difference in reoperation rate or local recurrences were found. Oncoplastic BCS is as safe as con-
ventional BCS enabling breast conserving for patients who otherwise were candidates for mastectomy.
© 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical
Oncology. All rights reserved.Introduction
Breast conserving surgery (BCS), instead of mastectomy, has
long since established its role as the standard of surgical care in the
treatment of early-stage breast cancer. Oncoplastic BCS techniques
have further extended the possibilities of BCS into the treatment of
larger and multifocal tumours as well as extensive ductal carci-
noma in situ (DCIS), without compromising the oncological safety
or aesthetic outcome [1]. Oncoplastic BCS allow resections of up torehensive Cancer Center, P.O.
ki).
on for Cancer Surgery, and the Eur
Resection margins and local
pean Journal of Surgical Onco50% of breast volume without causing deformity.
Adequate surgical margins are decisive in reducing the risk of
local recurrence (LR) [2]. Positive surgical margins are generally
thought to necessitate a reoperation, either a re-excision, or a
mastectomy [3]. A second operation can cause discomfort and
stress to the patient, lead to an increased risk of surgical compli-
cations and to poor aesthetic outcome, delay adjuvant therapy and
increase health care costs [2,4e6]. Furthermore, the patients who
undergo a re-excision may have an increased risk of developing LR,
compared to patients with only one operation [7].
There are several studies reporting short- and even long-term
outcomes after oncoplastic BCS, mainly after reduction mammo-
plasty techniques [3,8e12]. Oncoplastic BCS, however, includesopean Society of Surgical Oncology. All rights reserved.
recurrences in breast cancer: Comparison between conventional and
logy, https://doi.org/10.1016/j.ejso.2019.02.010
Abbreviations
BCS Breast conserving surgery
DCIS ductal carcinoma in situ
LR local recurrence
RT radiotherapy
CNB core needle biopsy
FNAC ﬁne needle aspiration cytology
ROLL radioguided occult lesion localization
MRI magnetic resonance imaging
SNB sentinel node biopsy
MDT multidisciplinary team
CT computed tomography scan
LRFS local recurrence free survival
L. Niinikoski et al. / European Journal of Surgical Oncology xxx (xxxx) xxx2several different techniques [1], which differ substantially
regarding the amount of resected tissue.
This retrospective cohort study aims to compare surgical mar-
gins, reoperations and LR after conventional or oncoplastic BCS. In
addition, we aim to investigate differences between various onco-
plastic BCS techniques.
Patients and methods
Consecutive patients with primary invasive breast cancer or
DCIS who underwent BCS at Breast Surgery Unit of Helsinki Uni-
versity Hospital between the January 1st, 2010 and December 31st,
2012 were included in this retrospective cohort study. We excluded
the patients who underwent merely a tumourectomy with neither
adjuvant treatment nor axillary surgery due to comorbidities
(N¼ 29). In addition, we excluded the patients who had been
diagnosed by surgical biopsy (N¼ 45) and those whose breast
cancer was found unexpectedly in reduction mammoplasty spec-
imen (N¼ 2). Remaining 1800 cases were categorized into two
groups, conventional or oncoplastic BCS. None of the patients had
received neoadjuvant treatment.
The data was collected from electronic patient records: patient
and tumour characteristics, surgical technique, excision margins
and specimenweight, re-excision rate, lymph node status, adjuvant
systemic treatment, postoperative radiotherapy (RT), time to local,
regional or distant recurrence, date and cause of death and date of
last follow-up. Patients with bilateral cancer were regarded as two
separate cases with possibly different BCS techniques.
Imaging
All patients underwent mammography as well as breast and
axillary ultrasound. Core needle biopsy (CNB) was taken from
breast lesion(s) and ﬁne needle aspiration cytology (FNAC) from
suspicious axillary lymph nodes. The patients who had an invasive
lobular carcinoma diagnosed on CNB underwent magnetic reso-
nance imaging (MRI) (N¼ 270).
Surgical technique
All breast and axillary operations were performed or supervised
by an experienced breast surgeon. Impalpable lesions were local-
ized either with radioguided occult lesion localization (ROLL),
hooked wire or radioactive seed. Surgeon had chosen the most
suitable operation technique individually depending on the loca-
tion and size of the tumour, as well as on the size and the glandular
density of breast, in agreement with the patient. In this study,Please cite this article as: Niinikoski L et al., Resection margins and local
oncoplastic breast conserving surgery, European Journal of Surgical Oncoconventional BCS stands for resection of the tumour with adequate
mobilization and closure of breast tissue. Oncoplastic BCS instead
refers to other level 1 and level 2 oncoplastic procedures [1].
The patients who had been diagnosed with axillary lymph node
metastasis in ultrasound guided FNAC underwent axillary lymph
node dissection. Sentinel node biopsy (SNB) was performed in
patients with invasive breast cancer, node negative in axillary ul-
trasound. The patients with DCIS but a suspicion of invasion in CNB
underwent SNB likewise.
Reoperation due to inadequate margins was either a re-excision
or a mastectomy depending on breast size, glandular density and
aesthetic result after the ﬁrst operation, with patient's preference
taken into account. The guidelines for adequate surgical margins
changed at the beginning of the study period in 2010 and new
recommendations were adopted in our unit gradually. Previously
5mmmicroscopical histological margins were required for invasive
cancer and 10mm for DCIS. Consensus symposium in 2010 rec-
ommended that no ink on tumour is adequate for invasive cancer
and 2mm for DCIS with or without concomitant invasive tumour
[13].
Histopathological examination
Histopathological analyses from surgical specimens were per-
formed by experienced breast pathologists. The breast and lymph
node specimens were handled and examined as described in our
earlier study [14].
Adjuvant treatment
All cases were discussed at a multidisciplinary team (MDT)
meeting after surgery in order to recommend adjuvant treatments.
All patients received postoperative RT except thosewho underwent
mastectomy as a second operation and those whose general con-
dition was not suitable for RT. The patients who had distant
metastasis identiﬁed on postoperative whole body computed to-
mography scan (CT) did not receive RT either. Adjuvant chemo-
therapy and endocrine treatment were recommended according to
the Finnish national evidence-based guidelines [15]. The patients
with DCIS or with luminal T1a-b invasive, node negative breast
cancer do not receive adjuvant systemic treatment. The RT and
adjuvant systemic treatment protocols used at our institution are
described in our earlier study [16].
Follow-up
The ﬁrst clinical checkup took placewithin threeweeks after the
operation. After adjuvant chemotherapy and/or radiotherapy the
patients were followed-up for ﬁve years. Very young women and
women with hereditary breast cancer were followed-up for ten
years at the Department of Oncology of Helsinki University Hos-
pital. The follow-up consisted of visits at one, three and ﬁve years
after the operation. In addition, a phone service operated by a
breast cancer nurse practitioner was available for patients who
needed counselling about symptoms related to side-effects of
treatments or potential recurrence. The patients had a possibility
for further visits if needed.
Mammography was performed yearly and combined with ul-
trasound in women 45 years or older with high density of breast
in mammography or if needed as further diagnostic investigation.
Annual MRI of the breasts was performed in womenwith high risk
hereditary breast cancer. Additionally, MRI, whole body CT or bone
isotope scan were done whenever indicated for instance due to
symptoms which might indicate local or distant recurrence.
After the ﬁrst ﬁve years or in some patients after ten years therecurrences in breast cancer: Comparison between conventional and
logy, https://doi.org/10.1016/j.ejso.2019.02.010
L. Niinikoski et al. / European Journal of Surgical Oncology xxx (xxxx) xxx 3follow-up continued at primary health care.Statistics
Statistical analyses were performed using IBM™ SPSS™ Statis-
tics version 22 software (SPSS Inc., Chicago, IL). Frequency tables
were analyzed with chi-squared test and continuous distributions
with Mann-Whitney U test.
For LR survival analysis and for other breast cancer events, we
excluded the patients with bilateral disease (N¼ 87), earlier breast
cancer (N¼ 69), other malignancy within ﬁve years (apart from
DCIS or basal cell carcinoma, N¼ 105), distantmetastasis diagnosed
within 12 months after primary operation (N¼ 18) and those who
underwent a completion mastectomy (N¼ 80). In addition, we
excluded the patients who were followed-up for less than threeTable 1
Patient and tumour characteristics for conventional and oncoplastic breast conserving su
Conve
N
Tumour Impalpable 750
Palpable 439
Reoperation due to No 1093
insufﬁcient margins Yes 96
Reoperation Re-excision 42
Mastectomy 54
Histology DCIS 64
Invasive ductal carcinoma 826
Invasive lobular carcinoma 136
Other invasive 163
Pathological T stage pTis 64
pT1 990
pT2 132
pT3 2
pT4 1
Multifocal tumour No 1066
Yes 123
EIC 0 1077
1 112
Tumour grade 1 416
2 500
3 272
NA 1
ER Negative 100
Positive 1028
NA 61
PR Negative 303
Positive 825
NA 61
Ki-67 0e15% 680
16e30% 260
>30% 183
NA 61
HER Negative 1032
Positive 96
NA 61
Lymph node status pN0 891
pN1mic 85
pN1mac 213
Radiotherapy No 63
Yes 1126
Adjuvant treatment No 317
Endocrine treatment 512
Chemotherapy 61
Both 299
Median (range) Media
Age (years) 62 (35e93) 61 (37
Tumour size (mm) 12 (1e86) 16 (1e
Smallest lateral surgical margin (mm) 10 (0e40) 10 (0e
Specimen weight (g) 56 (8e507) 77 (10
Abbreviations: BCS, breast conserving surgery; DCIS, ductal carcinoma in situ; EIC, extens
proliferation marker; HER, Human Epidermal Growth Factor Receptor; NA, Not available
Please cite this article as: Niinikoski L et al., Resection margins and local
oncoplastic breast conserving surgery, European Journal of Surgical Oncoyears due to relocation to other hospital district (N¼ 30). The
remaining 1411 patients went through a Kaplan-Meier survival
analysis for local recurrence-free survival (LRFS), the conventional
and oncoplastic BCS groups were compared with the log-rank test.
Other breast cancer events were assessed with Fisher's exact test
simply comparing event counts.
This retrospective study did not require an ethics committee
permission, but was approved by the institutional research board of
Helsinki University Hospital.Results
The patient and tumour characteristics are summarized in
Table 1. 1707 patients had invasive breast cancer and 93 had DCIS.
Conventional BCS was performed in 1189 patients (66.1%) andrgery.
ntional BCS N¼ 1189 Oncoplastic BCS N¼ 611 p-value
% N %
63.1% 255 41.7% <0.001
36.9% 356 58.3%
91.9% 555 90.8% 0.430
8.1% 56 9.2%
43.8% 17 30.4% 0.102
56.3% 39 69.6%
5.4% 29 4.7% 0.877
69.5% 424 69.4%
11.4% 76 12.4%
13.7% 82 13.4%
5.4% 28 4.6% <0.001
83.3% 415 67.9%
11.1% 164 26.8%
0.2% 3 0.5%
0.1% 1 0.2%
89.7% 512 83.8% <0.001
10.3% 99 16.2%
90.6% 538 88.1% 0.094
9.4% 73 11.9%
35.0% 175 28.6% <0.001
42.1% 237 38.8%
22.9% 198 32.4%
0.1% 1 0.2%
8.4% 68 11.1% 0.171
86.5% 512 83.8%
5.1% 31 5.1%
25.5% 184 30.1% 0.108
69.4% 396 64.8%
5.1% 31 5.1%
57.4% 291 47.6% <0.001
22.0% 155 25.4%
15.5% 134 21.9%
5.1% 31 5.1%
86.8% 505 82.6% 0.016
8.1% 75 12.3%
5.1% 31 5.1%
74.9% 415 67.9% <0.001
7.1% 36 5.9%
17.9% 160 26.2%
5.3% 31 5.1% 0.839
94.7% 580 94.9%
26.7% 85 13.9% <0.001
43.1% 234 38.3%
5.1% 62 10.1%
25.1% 230 37.6%
n (range)
e86) <0.001
80) <0.001
56) 0.578
e1893) <0.001
ive intraductal component; ER, estrogen receptor; PR, progesterone receptor; Ki-67,
.
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used, these are provided in Table 3. The percentage of patients with
pure DCIS was similar in conventional BCS group (5.4%) and in
oncoplastic BCS group (4.7%) (p¼ 0.877).
Patients with oncoplastic BCS had more often multifocal
(p< 0.001), larger (p< 0.001), and palpable tumours (p< 0.001)
with larger resection specimens (p< 0.001). The amount of resec-
ted tissue varied substantially depending on the oncoplastic tech-
nique. Median specimen weight was 56 g in conventional BCS
group and 77 g in oncoplastic group (p< 0.001). The range of
specimen weight was wide in the oncoplastic group (10e1893 g).
Patients treated with oncoplastic BCS were slightly younger
(p< 0.001) and their tumours were more aggressive according to
histological grade (p< 0.001), T-stage (p< 0.001), Ki-67 prolifera-
tion index (p< 0.001) and lymph node status (p< 0.001).Table 2
Patient and tumour characteristics for reoperations due to inadequate margins.
Reoperation d
Yes N¼ 152 (8
N
Surgery Conventional BCS 96
Oncoplastic BCS 56
Tumour Impalpable 73
Palpable 79
Reoperation Re-excision 59
Mastectomy 93
Histology DCIS 14
Invasive ductal carcinoma 98
Invasive lobular carcinoma 26
Other 14
Multifocal tumour No 85
Yes 67
EIC No 115
Yes 37
Tumour grade 1 36
2 67
3 49
NA 0
ER Negative 11
Positive 128
NA 13
PR Negative 39
Positive 100
NA 13
Ki-67 0e15% 66
16e30% 45
>30% 27
NA 13
HER Negative 124
Positive 15
NA 13
Lymph node status pN0 89
pN1mic 9
pN1mac 54
Radiotherapy No 60
Yes 92
Adjuvant treatment No 23
Endocrine treatment 50
Chemotherapy 9
Both 70
Median (range
Age (years) 59 (35e85)
Tumour size (mm) 16 (1e80)
Smallest lateral surgical margin (mm) 0.5 (0e10)
Specimen weight (g) 57 (12e660)
Abbreviations: BCS, breast conserving surgery; DCIS, ductal carcinoma in situ; EIC, extens
proliferation marker; HER, Human Epidermal Growth Factor Receptor; NA, Not available
Please cite this article as: Niinikoski L et al., Resection margins and local
oncoplastic breast conserving surgery, European Journal of Surgical OncoReoperations
There was no difference, however, in surgical margins
(p¼ 0.578) or reoperation rates (p¼ 0.430) between the groups
(Table 2). A total of 152 (8.4%) patients were reoperated because of
insufﬁcient margins, 96 (8.1%) in the conventional BCS group and
56 (9.2%) in the oncoplastic BCS group.
Risk factors for reoperations were multifocality of the tumour
(p< 0.001), larger tumour size and high pathological T-stage
(p< 0.001) and extensive intraductal component (EIC) (p< 0.001).
Of 222 patients withmultifocal tumours 67 (30.2%) underwent a
reoperation, compared to 85 out of 1578 (5.4%) patients with uni-
focal tumours. The median size of the tumours, in patients under-
going a reoperation, was 16mm (1e80mm). Of 185 patients with
EIC, 37 (20.0%) underwent a reoperation compared to 115 (7.1%) of
1615 without EIC.ue to inadequate margins
.4%) No N¼ 1648 (91.6%) p-value
% N %
8.1% 1093 91.9% 0.430
9.2% 555 90.8%
7.3% 932 92.7% 0.043
9.9% 716 90.1%
38.8% 0 0.0%
61.2% 0 0.0%
15.1% 79 84.9% 0.007
7.8% 1152 92.2%
12.3% 186 87.7%
5.7% 231 94.3%
5.4% 1493 94.6% <0.001
30.2% 155 69.8%
7.1% 1500 92.9% <0.001
20.2% 148 80.0%
6.1% 555 93.9% 0.066
9.1% 670 90.9%
10.4% 421 89.6%
0.0% 2 100.0%
6.5% 157 93.5% 0.097
8.3% 1412 91.7%
14.8% 79 85.9%
8.0% 448 92.0% 0.131
8.2% 1121 91.8%
14.1% 79 85.9%
6.8% 905 93.2% 0.016
10.8% 370 89.2%
8.5% 290 91.5%
14.1% 79 85.9%
8.1% 1413 91.9% 0.125
8.8% 156 91.2%
14.1% 79 85.9%
6.8% 1217 93.2% <0.001
7.4% 112 92.6%
14.5% 319 85.5%
63.8% 34 36.2% <0.001
5.4% 1614 94.6%
5.7% 379 94.3% <0.001
6.7% 696 93.3%
7.3% 114 92.7%
13.2% 459 86.8%
) Median (range)
62 (35e93) 0.003
13 (1e86) <0.001
10.0 (0e56.0) <0.001
62 (8e1893) 0.231
ive intraductal component; ER, estrogen receptor; PR, progesterone receptor; Ki-67,
.
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mastectomy (69.6%) compared to conventional BCS group (56.3%),
but the difference was not statistically signiﬁcant (p¼ 0.102).
Oncoplastic BCS techniques
Eleven different oncoplastic BCS techniques were used (Table 3).
Racket mammoplasty (30.1%) and round block (28.0%) were the
most common methods. Only 55 patients were operated using
reduction mammoplasty techniques, superior or inferior pedicle
mammoplasty or wise-pattern reduction with resection of nipple-
areolar complex (wise-amputation). The reoperation rate ranged
from 5.0% (J-mammoplasty) to 29.4% (batwing mammoplasty), but
was similar in the most of the groups (7.7e10%). The number of
batwing-mammoplasty procedures (N¼ 17) was small in this
series.
Breast cancer recurrence
Altogether 1411 patients remained for survival analysis of LRFS,
940 in the conventional group and 471 in the oncoplastic BCS group
(Table 4). The median follow-up time was 75 (2e94) months. There
was no difference in LRFS between the conventional and onco-
plastic BCS groups in the Kaplan-Meier analysis (log-rank test,
p¼ 0.172, Fig. 1). The ﬁve-year LRF survival estimates for conven-
tional and oncoplastic BCS groups were 98.0% and 98.9%,
respectively.
Contralateral breast cancer recurrence and regional lymph node
recurrences are summarized in Table 4. Distant metastases were
detected in 29 (3.1%) patients in the conventional BCS group and in
16 (3.4%) patients in the oncoplastic BCS group (Fisher's test,
p¼ 0.750). Eight of the 32 (25.0%) patients with ipsilateral LR
developed distant metastasis as well. Six of them were diagnosed
with ipsilateral LR concomitantly with distant disease, one had
ipsilateral LR as a primary event and one distant metastasis ﬁrst.
In total, 73 patients died during the follow-up, 56 (6.0%) in the
conventional BCS group and 17 (3.6%) in the oncoplastic BCS group
(Fisher's test, p¼ 0.074). Eighteen (1.9%) patients in the conven-
tional group and seven (1.5%) in the oncoplastic BCS group died
from breast cancer (Fisher's test, p¼ 0.672).
Discussion
Main message
Our study indicates that oncoplastic BCS is as safe as conven-
tional BCS even though oncoplastic techniques were used for larger,
multifocal andmore aggressive tumours. We found no difference in
surgical margins, reoperation rates nor LR rates between theTable 3
Oncoplastic breast conserving surgery techniques.
N Smallest lateral surgical margin (mm)
Median (range)
Racket 184 10.0 (0e45.0)
Round block 171 10.0 (0e30.0)
Upper rotation 67 10.0 (0e30.0)
Lower rotation 50 10.0 (0e20.0)
Superior pedicle 37 12.0 (0e35.0)
inferior pedicle 10 14.0 (2.0e20.0)
Mastopexy 26 7.5 (1.0e30.0)
S-plasty 21 10.0 (0e56.0)
J-plasty 20 12.5 (0.3e30.0)
Batwing 17 5.0 (0e15.0)
Wise-amputation 8 26.5 (9.0e50.0)
Please cite this article as: Niinikoski L et al., Resection margins and local
oncoplastic breast conserving surgery, European Journal of Surgical Oncogroups.
In this study, we wanted to put a special focus on evaluating
results between different oncoplastic techniques. The concept of
oncoplastic BCS includes a broad range of varying surgical tech-
niques; some techniques are appropriate for small sized tumours
and breasts and others for multifocal and large tumours or for large
breasts. There are many studies assessing results after oncoplastic
reduction mammoplasty surgery, but only few reports on other
oncoplastic BCS techniques.
Resection margins and reoperations
In our series, reoperation rate was low (8.4%). Tumour size,
multifocal disease and EIC proved to be predictors of inadequate
margins. This is consistent with several other previous studies
[8,17e19]. A trend towards a higher risk of reoperation in the DCIS
group (15.1%) and in the invasive lobular carcinoma group (12.3%)
was observed, as reported earlier [8,11,20], yet this did not reach
statistical signiﬁcance (p¼ 0.007).
The reoperation rate after oncoplastic BCS was 9.2% and it was
similar in most of the oncoplastic BCS groups, although the amount
of resected tissue ranged considerably. We decided not to compare
each oncoplastic BCS technique statistically against each other, as
the number of patients in many of the groups is very small.
The positive margin rate in our study is comparable to the rates
reported earlier in the studies of oncoplastic BCS by Clough et al.
(12.6%) [8], De La Cruz et al. (10.8%) [3], Hillberg et al. (9.3%) [10],
Romics et al. (10.4%) [11] and Losken et al. (12.3%) [12]. Rietjens
et al. [9] reported a lower positive margin rate (5.4%) and Wijgman
et al. a higher rate (22.6%) [20] compared to our study. In all of these
studies the margins were heterogeneously classiﬁed and not
analyzed according to different oncoplastic techniques. On the
other hand, the tumours were larger in diameter in most of these
studies (15e27mm) compared to our results.
The median specimen weight in our series was 77 g. Not sur-
prisingly, it was highest in patients with reduction mammoplasty
techniques. The lowest median specimen weight resulted after
round block, J-mammoplasty and batwing techniques. The spec-
imen weights in previous studies were often higher (168e249g).
They reported, however, mainly breast reduction and ﬂap tech-
niques [3,8,9,12].
In cases of inadequate surgical margins, the reoperation was
more often a completion mastectomy in the oncoplastic BCS group
than in the conventional BCS group. Oncoplastic technique was
chosen primarily for larger or multifocal tumour in order to avoid
mastectomy. After the oncoplastic BCS a re-excision might have
compromised the aesthetic result. Thus, mastectomy was per-
formed more often as the second procedure in the oncoplastic BCS
group.Specimen weight (g) Reoperation due to insufﬁcient margins
Median (range) N (%)
80 (15e707) 18 (9.8)
54 (10e183) 14 (8.2)
121 (23e392) 6 (9.0)
66 (28e726) 4 (8.0)
331 (12e1180) 3 (8.1)
495 (168e1546) 1 (10)
80 (16e256) 2 (7.7)
538 (44e1255) 2 (9.5)
55 (24e312) 1 (5.0)
58 (18e288) 5 (29.4)
1604 (110e1893) 0 (0)
recurrences in breast cancer: Comparison between conventional and
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Table 4
Breast cancer events observed during follow-up.
Event Conventional BCS (N¼ 940) Oncoplastic BCS (N¼ 471) p-value (Fisher)
N (%) N (%)
Ipsilateral breast recurrence 25 (2.7%) 7 (1.5%) 0.188
Contralateral breast recurrence 12 (1.3%) 4 (0.8%) 0.599
Regional lymph node recurrence 10 (1.1%) 3 (0.6%) 0.562
Ipsilateral axillaa 4 (0.4%) 2 (0.4%)
Contralateral axillab 2 (0.2%) 0
Supraclavicular node 4 (0.4%) 1 (0.2%)
Distant metastasisc 29 (3.1%) 16 (3.4%) 0.750
Death from breast cancer 18 (1.9%) 7 (1.5%) 0.672
Death from any cause 56 (6.0%) 17 (3.6%) 0.074
a Five patients had concomitant LR.
b Both of the patients had concomitant LR.
c Eight patients had ipsilateral LR concomitantly with distant disease, one had ipsilateral LR as a primary event and distant metastasis later, one had distant metastasis ﬁrst
and LR later.
Fig. 1. Kaplan-Meier survival analysis for local recurrence-free survival after conven-
tional and oncoplastic breast conserving surgery.
L. Niinikoski et al. / European Journal of Surgical Oncology xxx (xxxx) xxx6Waiting time for adjuvant treatment is discussed in our previous
study, which included patients who underwent BCS in 2010 at our
institution [21]. There was no difference in median waiting time
between conventional and oncoplastic surgery (47 vs. 48 days).Local recurrences
In our study, the ipsilateral LR rate during a median of 75
months follow-up was 2.3%. This is comparable to other studies.
Romics et al. [11] reported a LR rate of 2.7% during a median of 30
months follow-up, Clough et al. a LR rate of 2.2% during a median of
55 months follow-up [8] and Rietjens at al. [9] a LR of 3.4% during a
median of 74 months follow-up. In a systematic literature review
[3] the LR rate was 3.2% during a mean of 50.5 months follow-up
and 6.0% if the follow-up was more than ﬁve years. Contralateral
breast cancer recurrences and regional lymph node recurrences
were rare in our series.Strengths and limitations of the study
Our study examined a large number of patients and it was car-
ried out in a single institution. Our examination and treatment
protocols including surgical practice are standardized. We reportPlease cite this article as: Niinikoski L et al., Resection margins and local
oncoplastic breast conserving surgery, European Journal of Surgical Oncohere several different oncoplastic techniques, both level 1 and level
2, not merely oncoplastic reduction mammoplasty techniques.
Thereby, our study displays the entire spectrum of various onco-
plastic techniques used in our center in real-life clinical practice
and in an unselected cohort of breast cancer patients.
Limitation of this study is the retrospective design. The guide-
lines for adequate surgical margins changed at the beginning of
year 2010 and the newmargin recommendation ‘no ink on tumour’
was adopted gradually, therefore the indication for reoperation is
not standard throughout the study period. Furthermore, the in-
dications for reoperations are not similar in different units, which
hinders the comparison with other studies.
We did not assess the aesthetic outcome of BCS in this study, as
it is reported in our earlier study [22]. We did not record post-
operative complications either.
Conclusion
Oncoplastic BCS was used for larger, multifocal and more
aggressive tumours. Nevertheless, no difference in reoperation rate
or LR rate were found. Oncoplastic BCS is as safe as conventional
BCS enabling breast conserving for patients who otherwise were
candidates for mastectomy.
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